Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Urology Times

The PET agent targeting prostate specific membrane antigen (PSMA) 18F-DCFPyL effectively detected recurrent lesions in prostate cancer patients with biochemical